About Cellino
Cellino is a company based in Cambridge (United States) founded in 2017 by Matthias Wagner, Marinna Madrid, and Nabiha Saklayen. Cellino has raised $125 million across 6 funding rounds from investors including Khosla Ventures, Leaps by Bayer and 8VC. The company has 63 employees. Cellino offers products and services including Nebula Platform and Autologous iPSC Therapy. Cellino operates in a competitive market with competitors including Sana Biotechnology, Semma Therapeutics, Adocia, UCB and Rezolute, among others.
- Headquarter Cambridge, United States
- Employees 63
- Founders Matthias Wagner, Marinna Madrid, Nabiha Saklayen
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website cellinobio.com
- Social LinkedIn X
- Legal Name Cellino Biotech, Inc.
- Total Equity Funding$125M (USD)
in 6 rounds
- Latest Funding Round$25M (USD), Series A
Sep 2024
- InvestorsKhosla Ventures
& 6 more
- Employee Count63
Products & Services of Cellino
Cellino offers a comprehensive portfolio of products and services, including Nebula Platform and Autologous iPSC Therapy.
AI-driven system for scalable biomanufacturing of personalized regenerative therapies
Treatments for degenerative diseases using patient-specific stem cells
Funding Insights of Cellino
Cellino has successfully raised a total of $125M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $25 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $125M
- Total Rounds 6
- Last Round Series A — $25M
- Investors Count 7
All 6 funding rounds of Cellino with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $25M | Series A | – | – | – |
| Jan 2022 | $80M | Series A | – | Leaps by Bayer, 8VC | |
| Feb 2021 | $16M | Seed | – | Khosla Ventures, Engine Ventures | |
| Aug 2019 | $2.5M | Seed | – | – | – |
| Dec 2017 | $1.5M | Seed | – | – | – |
| Nov 2017 | – | Grant | – | – |
7 investors in total: 7 institutional.
Investors in Cellino
Cellino has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, Leaps by Bayer and 8VC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life sciences sector | – | leaps.bayer.com | Leverkusen, Germany | |
Venture capital firm investing in technology, life sciences, and related sectors. | – | 8vc.com | - | |
Early-stage companies in science and technology are supported by Humboldt Fund. | 2020 | humboldtfund.com | - | |
Investments in technology startups are made by Felicis Ventures. | – | felicis.com | Menlo Park, United States | |
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Early-stage technology startups are funded by Engine Ventures venture capital. | – | engineventures.com | Cambridge, United States | |
Early-stage entrepreneurs are accelerated through MassChallenge's program. | – | masschallenge.org | Boston, United States |
Investor details for Cellino
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cellino
22 people are tracked at Cellino (12 in leadership, 10 in team); the tracked headcount is 63.
| Name | Role | Group |
|---|---|---|
Matthias Wagner | Co-Founder & CTO | Leadership |
Marinna Madrid | Co-Founder | Leadership |
Nabiha Saklayen | Co-Founder & CEO | Leadership |
Willie Reaves | Head Of Public Engagement | Leadership |
Rebecca Kusko | Head, Corporate Strategy & Affairs | Leadership |
Christopher Harrison | Director of R&D | Leadership |
Blair Morad | Senior Director of Engineering | Leadership |
Abhijit Kulkarni | Chief Operating Officer | Leadership |
Lourdes Silva | Program Director | Leadership |
Ralitsa Mintcheva | Head of Finance | Leadership |
Deniz Aksel | Head Of Bioengineering | Leadership |
Suvi Aivio | Head, Biology | Leadership |
Matthew Sullivan | Manager, Optical Engine | Team |
Erik Snow | Principal Automation Engineer | Team |
Diwakar Cherukumilli | Principal Solutions Architect | Team |
Lukas Vasadi | Electromechanical Engineer | Team |
José Valdez | Mechanical Engineer | Team |
Mahder Haile | Bioprocess Operations Senior Associate | Team |
Jacqueline Nelson | Bioprocess Engineer | Team |
Taufiq Dhanani | Senior Backend Engineer | Team |
2 more people are available in the full profile.
Complete people profiles for Cellino
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cellino
3 dated milestones of Cellino across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Cellino is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $25.0M.
Competitors of Cellino
Cellino operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Semma Therapeutics, Adocia, UCB and Rezolute, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| adocia.com | 2005 | Lyon, France | $26M | – | Therapeutics for diabetes and obesity treatment are developed. | |
| ucb.com | 1928 | Brussels, Belgium | – | 79 | Therapies for immunological and neurological disorders are developed. | |
| rezolutebio.com | 2012 | Denver, United States | – | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | |
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| arrakistx.com | 2015 | Waltham, United States | $113M | 91 | Provider of tools for the analysis of RNA structures | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. |
Detailed competitors of Cellino
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cellino
The website of Cellino (cellinobio.com) receives about 5.5K visits a month and ranks #5,120,503 among all websites worldwide, #5,875 in Biotechnology and Pharmaceuticals.
- Monthly visits5.5K
▲ 64.6% vs previous month
- Unique visitors1.5K
per month
- Global rank#5,120,503
among all websites
- Category rank#5,875
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.6
- Average visit56 sec
- DevicesDesktop 61% · Mobile 39%
Websites whose visitors overlap most with Cellino. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| arpa-h.gov | 100% | – | #506,498 | View details | |
jobs.felicis.com | jobs.felicis.com | 51% | – | – | – |
Latest news on Cellino
Complete news archive for Cellino
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cellino
10 companies that operate in the same segment as Cellino (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cellino
Cellino was founded in 2017.
Cellino is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Nabiha Saklayen is the current CEO of Cellino. They have also founded this company.
Cellino is a funded company, having raised a total of $125M across 6 funding rounds to date.
Cellino has 63 employees.
Cellino was founded in 2017 in Cambridge, United States, and operates in the biotechnology sector focused on regenerative medicine. An AI-guided laser editing platform, single-cell laser processing, and robotics are utilized to generate autologous induced pluripotent stem cells. These therapies target diseases such as Parkinsons, diabetes, and heart disease, with operations centered on advancing cell-based treatments for clinical applications.
Cellino's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Cellino offers Nebula Platform and Autologous iPSC Therapy.
Cellino has 7 investors. Key investors include Khosla Ventures, Leaps by Bayer, 8VC, Humboldt Fund, and Felicis Ventures.
Cellino operates through Cellino Biotech, Inc..